Product Information
FT IBUPROFEN PM 200-38 MG CPLT is a generic product labeled by Strategic Sourcing Services LLC, priced at $0.1307 per EA under NDC 70677113101. Its NADAC has been published 113 times since Aug 7, 2024.
FDA first approved this application on Dec 22, 2008.
Strength
38; 200 mg/1; mg/1
Manufacturer
Strategic Sourcing Services LLCNDC
70677113101
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DIPHENHYDRAMINE CITRATE; IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA079113FDA Approved
12/22/2008
On Market Since
11/1/2023
Pharmacological Classes
Price Statistics
The NADAC for FT IBUPROFEN PM 200-38 MG CPLT has been published 113 times since Aug 7, 2024, and over the history we have for it it has risen 4.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1307 per EA |
|---|---|
| All-time high | $0.1313 (Sep 16, 2026) |
| All-time low | $0.1220 (Nov 20, 2024) |
| 52-week high | $0.1313 |
| 52-week low | $0.1249 |
| Median price | $0.1257 |
| Average price | $0.1260 |
| Largest weekly change | +3.3% (Oct 23, 2024) |
| Weeks tracked | 113 |
| Tracking since | Aug 7, 2024 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strategic Sourcing Services LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
diphenhydramine citrate, ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FT IBUPROFEN PM 200-38 MG CPLT?
The current National Average Drug Acquisition Cost (NADAC) for FT IBUPROFEN PM 200-38 MG CPLT, manufactured by Strategic Sourcing Services LLC, is $0.1307 per EA (NDC 70677113101), effective Sep 30, 2026.
How has the price of FT IBUPROFEN PM 200-38 MG CPLT changed over time?
Over the history we have for it, the NADAC for FT IBUPROFEN PM 200-38 MG CPLT has risen 4.6%. It has been tracked across 113 weekly CMS publications since Aug 7, 2024.
What are the highest and lowest recorded NADAC prices for FT IBUPROFEN PM 200-38 MG CPLT?
Since Aug 7, 2024, the NADAC for FT IBUPROFEN PM 200-38 MG CPLT has ranged from a low of $0.1220 (Nov 20, 2024) to a high of $0.1313 (Sep 16, 2026), with a median of $0.1257 per EA.
Are there cheaper alternatives to FT IBUPROFEN PM 200-38 MG CPLT?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IBUPROFEN PM CAPLET, is $0.1250 per EA — about 4% below FT IBUPROFEN PM 200-38 MG CPLT.
Who manufactures FT IBUPROFEN PM 200-38 MG CPLT?
FT IBUPROFEN PM 200-38 MG CPLT (NDC 70677113101) is labeled by Strategic Sourcing Services LLC, and CMS classifies it as a generic product.